SCHEMBL17666285

SCHEMBL17666285

Cc1ccc(-c2ccnnc2)c(C)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
WNT3A P56704 5/20 0.46
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
CYP17A1 P05093 1/20 0.42
MAPT P10636 4/20 0.40
TP53 P04637 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
TDP1 Q9NUW8 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
LMNA P02545 1/20 0.38
CYP46A1 Q9Y6A2 1/20 0.38
ALPL P05186 1/20 0.38
CA9 Q16790 1/20 0.38
ESR2 Q92731 2/20 0.38
ESR1 P03372 1/20 0.38
GAA P10253 1/20 0.37
S1PR1 P21453 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27778798 0.81 NPC1 (0.47) WNT3ANPC1RAB9AMEN1KMT2A
SCHEMBL16982970 0.81 NOTUM (0.46) WNT3ASMN1; SMN2
SCHEMBL8358833 0.78 NISCH (0.45) MAPTSMN1; SMN2NPSR1
SCHEMBL13393498 0.78 NPC1 (0.60) NPC1RAB9AMEN1KMT2ACYP17A1
SCHEMBL5318296 0.76 TRPA1 (0.41) WNT3ANPC1RAB9ASMN1; SMN2CA9
SCHEMBL13393530 0.76 NPC1 (0.64) NPC1RAB9ACYP17A1MAPTTP53
SCHEMBL17244895 0.75 TRPA1 (0.46) LMNA
SCHEMBL17432889 0.74 WNT3A (0.39) WNT3AS1PR1
SCHEMBL20188635 0.74 SCN5A (0.49) WNT3A
SCHEMBL28295766 0.74 WNT3A (0.42) WNT3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170002006-A1 MACROCYCLES WITH HETROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-01-05 US disclosed
US-20160368923-A1 PYRIMIDINONES AS FACTOR XIA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2016-12-22 US disclosed
US-9453018-B2 Pyrimidinones as factor XIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2016-09-27 US disclosed
US-20160096839-A1 PYRIMIDINONES AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2016-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160368923-A1 PYRIMIDINONES AS FACTOR XIA INHIBITORS TFPI, TFPI2, F2 WNT3A 3391/4885NPC1 3590/4885RAB9A 2644/4885
US-20170002006-A1 MACROCYCLES WITH HETROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS TFPI2, F2, TFPI WNT3A 1728/4885NPC1 2295/4885RAB9A 3652/4885
US-20160096839-A1 PYRIMIDINONES AS FACTOR XIA INHIBITORS TFPI, TFPI2, F2 WNT3A 3391/4885NPC1 3590/4885RAB9A 2644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.